ArticleNPJ breast cancer2024

Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).

Magdalena Mileva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.